Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi

suck pdf from helios

10.1016/j.ijantimicag.2020.106053

http://scihub22266oqcxt.onion/10.1016/j.ijantimicag.2020.106053
suck pdf from google scholar
32534189!7286256!32534189
unlimited free pdf from europmc32534189    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32534189 :   free
PDF vom PMID32534189  :  Publisher
PDF vom PMID32534189

suck abstract from ncbi

pmid32534189
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Macrolides and viral infections: focus on azithromycin in COVID-19 pathology #MMPMID32534189
  • Pani A; Lauriola M; Romandini A; Scaglione F
  • Int J Antimicrob Agents 2020[Aug]; 56 (2): 106053 PMID32534189show ga
  • The emergence of the new COVID-19 virus is proving to be a challenge in seeking effective therapies. Since the most severe clinical manifestation of COVID-19 appears to be a severe acute respiratory syndrome, azithromycin has been proposed as a potential treatment. Azithromycin is known to have immunomodulating and antiviral properties. In vitro studies have demonstrated the capacity of azithromycin in reducing production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress, and modulate T-helper functions. At the same time there are multiple clinical evidences of the role of azithromycin in acute respiratory distress syndrome and against Middle East Respiratory syndrome (MERS). Some preliminary evidence has demonstrated controversial results regarding efficacy of azithromycin in combination with hydroxychloroquine in COVID-19. First, a French trial demonstrated 100% virological negativizing of six patients treated with azithromycin plus hydroxychloroquine vs. 57.1% of patients treated with only hydroxychloroquine and 12.5% of the control group (P < 0.05). On the other hand, another case series revealed no efficacy at all on 11 patients treated with the same combination and doses. Furthermore, there are some concerns regarding the association of azithromycin and hydroxychloroquine because of potential QT prolongation. In fact, both drugs have this as a potential side effect and evidence regarding the safe use of this combination is controversial. Despite the necessity to quickly find solutions for COVID-19, extreme caution must be used in evaluating the risk-benefit balance. However, based on preclinical and clinical evidence and some preliminary results in COVID-19, azithromycin could have potential in the fight against this new disease.
  • |Antiviral Agents/administration & dosage/adverse effects/therapeutic use[MESH]
  • |Azithromycin/administration & dosage/adverse effects/*therapeutic use[MESH]
  • |Betacoronavirus/*isolation & purification[MESH]
  • |Coronavirus Infections/*drug therapy/*pathology/virology[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use[MESH]
  • |Immunologic Factors/administration & dosage/adverse effects/therapeutic use[MESH]
  • |Long QT Syndrome/chemically induced[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/*pathology/virology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    106053 2.56 2020